Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment

World News: . []

New York Nov 08 2018 GLOBE NEWSWIRE -- Intrommune Therapeutics a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is pleased to announce the first close of its Series A prefe...

More news and information about Intrommune Therapeutics

Published By:

Globe Newswire: 21:44 GMT Thursday 8th November 2018

Published: .

Search for other references to "intrommune" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us